Inhibition of T-cell activity in alopecia areata: recent developments and new directions - Archive ouverte HAL
Article Dans Une Revue Frontiers in Immunology Année : 2023

Inhibition of T-cell activity in alopecia areata: recent developments and new directions

B. King
  • Fonction : Auteur
M. Steinhoff
  • Fonction : Auteur
A. Jabbari
  • Fonction : Auteur
M. Ohyama
  • Fonction : Auteur
D.J. Tobin
  • Fonction : Auteur
S. Randhawa
  • Fonction : Auteur
A. Winkler
  • Fonction : Auteur
Jean-Baptiste Telliez
  • Fonction : Auteur
D. Martin
  • Fonction : Auteur
A. Lejeune
  • Fonction : Auteur

Résumé

Alopecia areata (AA) is an autoimmune disease that has a complex underlying immunopathogenesis characterized by nonscarring hair loss ranging from small bald patches to complete loss of scalp, face, and/or body hair. Although the etiopathogenesis of AA has not yet been fully characterized, immune privilege collapse at the hair follicle (HF) followed by T-cell receptor recognition of exposed HF autoantigens by autoreactive cytotoxic CD8+ T cells is now understood to play a central role. Few treatment options are available, with the Janus kinase (JAK) 1/2 inhibitor baricitinib (2022) and the selective JAK3/tyrosine kinase expressed in hepatocellular carcinoma (TEC) inhibitor ritlecitinib (2023) being the only US Food and Drug Administration–approved systemic medications thus far for severe AA. Several other treatments are used off-label with limited efficacy and/or suboptimal safety and tolerability. With an increased understanding of the T-cell–mediated autoimmune and inflammatory pathogenesis of AA, additional therapeutic pathways beyond JAK inhibition are currently under investigation for the development of AA therapies. This narrative review presents a detailed overview about the role of T cells and T-cell–signaling pathways in the pathogenesis of AA, with a focus on those pathways targeted by drugs in clinical development for the treatment of AA. A detailed summary of new drugs targeting these pathways with expert commentary on future directions for AA drug development and the importance of targeting multiple T-cell–signaling pathways is also provided in this review.
Fichier principal
Vignette du fichier
ImmuniConcept_FrontImmunol_2023_Passeron.pdf (2.18 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04709552 , version 1 (25-09-2024)

Licence

Identifiants

Citer

Thierry Passeron, B. King, Julien Seneschal, M. Steinhoff, A. Jabbari, et al.. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Frontiers in Immunology, 2023, 14, ⟨10.3389/fimmu.2023.1243556⟩. ⟨hal-04709552⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More